In a pooled analysis of the phase 3 ASCLEPIOS I/II trials in relapsing multiple sclerosis (RMS) patients, the effect of ofatumumab versus teriflunomide on confirmed disability progression independent of relapse activity (PIRA) was assessed. The risk of confirmed disability progression at 3/6 months (3mCDP/6mCDP) was evaluated in 3 subsets of patients:
A: without confirmed relapses during the study;
B: without confirmed relapses during the study or prior to a 3mCDP/6mCDP event;
C: with secondary progressive MS diagnosis at study entry and without confirmed relapses during the study.
In all subsets, ofatumumab significantly reduced the risk of 3mCDP and 6mCDP versus teriflunomide, except for 6mCDP in the small Subset-C (see Table). An inverse probability censoring weighted estimation of PIRA confirmed a significant risk reduction for ofatumumab versus teriflunomide of 46.0% for 3mCDP (HR 0.540; 95% CI 0.396-0.738; P<0.001) and 42.5% for 6mCDP (HR 0.575; 95% CI 0.409-0.808; P=0.001).
Table. Risk of 3mCDP and 6mCDP with ofatumumab versus teriflunomide [1].

n, number of patients with the specified event; N, total number of patients included in the analysis; 3mCDP, confirmed disability progression at 3 months; 6mCDP, confirmed disability progression at 6 months
In the superiority phase 3 OPTIMUM trial, the efficacy and safety of ponesimod and teriflunomide were compared [2,3] in 1,133 adult RMS patients (18-55 years) with an expanded disability status scale (EDSS) score of 0-5.5. They were randomised to ponesimod 20 mg or teriflunomide 14 mg once daily for 108 weeks.
The ARR for ponesimod and teriflunomide was 0.202 and 0.290, corresponding to a relative rate reduction (RRR) with ponesimod of 30.5% (P=0.0003). Respective mean change from baseline in fatigue symptom and impact questionnaire-RMS weekly symptoms score was 0.01 versus 3.57 (P=0.0019). Mean number of combined unique active lesions per year (CUALs) on MRI was 1.405 versus 3.164 (RRR 56%, P<0.0001). Time to 12- and 24-week confirmed disability accumulation risk estimates were reduced by 17% (P=0.29) and 16% (P=0.37), respectively.
In general, the safety of ponesimod and teriflunomide was comparable after 108 weeks [2]. Incidence of treatment-emergent adverse events (TEAEs) (88.8% vs 88.2%) and serious AEs (8.7% vs 8.1%) were similar. TEAEs leading to treatment discontinuation were 8.7% and 6.0%. Most common TEAEs were increased alanine aminotransferase levels (19.5% vs 9.4%), nasopharyngitis (19.3% vs 16.8%), headache (11.5% vs 12.7%), and upper respiratory tract infection (10.6% vs 10.4%).
- Kappos L, et al. Abstract O2034, EAN 2020.
- Kappos L, et al. Abstract S40.010, AAN 2020.
- Sprenger T, et al. Abstract P5.021, AAN 2020.
Posted on
Previous Article
« Switching from natalizumab to moderate- versus high-efficacy DMT Next Article
High NEDA rates after 2 years of ocrelizumab »
« Switching from natalizumab to moderate- versus high-efficacy DMT Next Article
High NEDA rates after 2 years of ocrelizumab »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimer’s disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinson’s disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles

September 10, 2020
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
September 9, 2020
Avoidable epilepsy-related mortality remains high
September 9, 2020
Unmet needs and pipeline
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy